ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...

ASLAN Pharmaceuticals’ Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer - K-MASTER, Korea’s leading precision medicine research group, to conduct phase 1b/2 umbrella study testing varlitinib as a second-line treatment in HER1/HER2 co-expressing advanced or metastatic...